Can semaglutide reduce cardiovascular events in non-diabetic patients?

What is the strongest evidence that semaglutide works for this?

The most definitive answer comes from the SELECT trial, a massive, high-quality study designed specifically to answer this question. It enrolled over 17,600 non-diabetic patients aged 45+ who were overweight or obese (BMI ≥27) and already had cardiovascular disease (like a prior heart attack or stroke). The results were clear: over an average of nearly 40 months, those taking weekly semaglutide (2.4 mg) had a 20% lower risk of a major cardiovascular event (a composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke) compared to those on placebo (6.5% vs. 8.0%) [2]. This is the cornerstone finding, and it's supported by a subsequent meta-analysis of multiple randomized controlled trials which confirmed a significant 19% reduction in major adverse cardiovascular events with semaglutide [6].

The SELECT trial also showed additional benefits. It found that semaglutide reduced the risk of a composite kidney outcome (including significant kidney function decline) by 22% compared to placebo [4]. This suggests the cardiovascular benefits are part of a broader protective effect. Furthermore, a cost-effectiveness analysis based on SELECT data concluded that using semaglutide in this specific patient population is cost-effective by standard US healthcare benchmarks, largely by preventing costly heart attacks, strokes, and the progression to diabetes [9].

Does it work for everyone, and what are the downsides?

The strongest evidence is for non-diabetic patients who are overweight or obese AND have established cardiovascular disease. This is the population studied in the SELECT trial [2]. A real-world registry study found that about 27% of patients after a heart attack would meet these SELECT criteria, suggesting a large group of people could potentially benefit [7]. However, the evidence is less certain for people without pre-existing heart disease. One large observational study using insurance claims data did find a 27% lower risk of a composite cardiovascular endpoint in lower-risk patients without prior heart disease [8], but this type of study can't prove cause and effect as strongly as a randomized trial. More research is needed before we can say the benefit extends to everyone who is overweight.

There are important downsides to consider. The most common side effects are gastrointestinal, like nausea and diarrhea, which are usually mild to moderate but can be persistent [10]. In the SELECT trial, 16.6% of patients on semaglutide stopped the drug due to side effects, compared to 8.2% on placebo [2]. A large real-world study also flagged a small but statistically significant increased risk of new-onset atrial fibrillation (a heart rhythm problem) and pancreatitis [3]. The benefit in reducing major cardiovascular events clearly outweighed these risks in the SELECT trial population, but these are important considerations for any individual deciding on treatment.

How does semaglutide compare to other similar drugs?

Semaglutide appears to be very effective, but a newer drug, tirzepatide, may be even more potent. One large real-world study directly compared tirzepatide (a dual GIP and GLP-1 receptor agonist) to semaglutide in non-diabetic obese adults. It found that tirzepatide was associated with a 14% lower risk of the composite cardiovascular outcome, driven largely by a greater reduction in new-onset heart failure [1]. Tirzepatide also led to greater weight loss (9.8 kg vs. 8.0 kg) [1]. This suggests that while semaglutide is a powerful option, tirzepatide might offer additional benefits, especially for heart failure prevention, though this was an observational study and not a head-to-head trial.

A meta-analysis of multiple studies comparing GLP-1 receptor agonists (the class of drugs that includes semaglutide) to placebo in non-diabetic patients found that the entire class significantly reduced cardiovascular events by about 25% [5]. Importantly, this same analysis found that semaglutide appeared to provide the greatest risk reduction among the different drugs in the class [5]. So, while other options exist, semaglutide stands out as a particularly effective choice for cardiovascular risk reduction in this population.

About These Sources

This answer is built on 10 peer-reviewed studies — published from 2021 to 2026, 8 from 2024 or later, 5 in Q1 journals, collectively cited 6,200 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 55 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions